Holen Sie sich die Stockscreener-App
22.75
0.70%
-0.16
Handel nachbörslich:
22.54
-0.21
-0.92%
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Stock Recap: Can Arcutis Biotherapeutics Inc sustain earnings growth2026 WrapUp & Expert-Curated Trade Recommendations - baoquankhu1.vn
The Technical Signals Behind (ARQT) That Institutions Follow - Stock Traders Daily
Arcutis reports long-term data on eczema cream for young children - Investing.com Canada
Arcutis reports long-term data on eczema cream for young children By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (ARQT) Reports Positive Findings from Zo - GuruFocus
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology - The Manila Times
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology - Bitget
Year-long eczema study: Arcutis cream eased symptoms in young kids - Stock Titan
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline - TipRanks
Arcutis (ARQT) Q4 2025 Earnings Call Transcript - AOL.com
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating - Yahoo Finance
GW&K Investment Management LLC Sells 206,391 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
10 Fastest Growing NASDAQ Stocks to Buy - Insider Monkey
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth - Sahm
Arcutis Promotes Mas Matsuda to Executive Vice President, Chief Legal Officer - Contract Pharma
Mas Matsuda Promoted to Executive Vice President and Chief Legal Officer at Arcutis Biotherapeutics - geneonline.com
Arcutis Biotherapeutics (ARQT) Elevates Legal Leader to Executiv - GuruFocus
Arcutis Biotherapeutics Promotes Mas Matsuda to Executive Vice President and Chief Legal Officer - Quiver Quantitative
Arcutis Announces Promotion of Mas Matsuda to Executive - GlobeNewswire
Lawyer behind six ZORYVE FDA wins takes top legal role at Arcutis - Stock Titan
Arcutis (ARQT) Earnings Call Signals Scaled Growth - TipRanks
Insider Sell Alert: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus
Arcutis (ARQT) director sells 39,272 shares under 10b5-1 plan - Stock Titan
Vanguard Group Inc. Buys 96,991 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 3,687 Shares - MarketBeat
Masaru Matsuda Sells 3,325 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Masaru Matsuda Sells 8,733 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Patrick Burnett Sells 6,287 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 37,349 Shares of Stock - MarketBeat
Arcutis (NASDAQ: ARQT) CFO gets RSU, option grants and sells shares - Stock Titan
Arcutis (ARQT) director Watanabe sells shares and receives large option, RSU awards - Stock Titan
Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial By Investing.com - Investing.com Australia
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New Trial Launch And Upgraded Revenue Outlook - simplywall.st
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis - Bitget
Arcutis Biotherapeutics Begins Enrollment for Phase 1a/1b Atopic Dermatitis Study - marketscreener.com
Arcutis Biotherapeutics (ARQT) Begins Phase 1 Study of ARQ-234 - GuruFocus
Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial - Investing.com
New Arcutis trial tests immune-checkpoint drug for atopic dermatitis - Stock Titan
Targets Report: Can Arcutis Biotherapeutics Inc deliver consistent EPS growth2025 Institutional Moves & Stock Timing and Entry Methods - baoquankhu1.vn
Masaru Matsuda reports Rule 144 share sales for Arcutis Biotherapeutics (NASDAQ: ARQT) - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) insider sale notice: 3,687 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 37,349 shares after vesting - Stock Titan
Mizuho cuts Arcutis stock price target to $35 on higher costs - Investing.com UK
Arcutis Biotherapeutics (ARQT) insider sale notice: 10,000 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 6.9% After Analyst Downgrade - MarketBeat
ARQT: Mizuho Lowers Price Target but Maintains Outperform Rating - GuruFocus
Mizuho Has Lowered Expectations for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price - MarketBeat
Research Analysts Offer Predictions for ARQT Q1 Earnings - MarketBeat
Precision Trading with Arcutis Biotherapeutics Inc. (ARQT) Risk Zones - Stock Traders Daily
Arcutis Biotherapeutics (ARQT) Is Up 6.1% After Raising 2026 Revenue Outlook And Turning Profitable - simplywall.st
ARQT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Arcutis Biotherapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ARQT) 2026-02-27 - Seeking Alpha
Arcutis Biotherapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in February 2026 - geneonline.com
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference - The Globe and Mail
Arcutis execs join TD Cowen health care conference March 2-4 - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $35.00 at Guggenheim - MarketBeat
Guggenheim Raises Price Target for ARQT to $35 | ARQT Stock News - GuruFocus
Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative? - Yahoo Finance
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Issues Pessimistic Outlook for ARQT Earnings - MarketBeat
Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference - Bitget
TD Cowen Raises Target Price for Arcutis Biotherapeutics (ARQT) to $35 | ARQT Stock News - GuruFocus
Arcutis Biotherapeutics (NASDAQ:ARQT) Given New $35.00 Price Target at TD Cowen - MarketBeat
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):